Use of topical misoprostol to reduce radiation-induced mucositis: Results of a randomized, double-blind, placebo-controlled trial

Australasian Radiology

Volumn 50, Issue 5, 2006, Pages 468-474

  Veness, M J ^a   Foroudi, F ^a,b   Gebski, V ^a   Timms, I ^a   Sathiyaseelan, Y ^a   Cakir, B ^a   Tiver, K W ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Head and neck; Oral; Quality of life; Xerostomia

Indexed keywords

ANALGESIC AGENT; BICARBONATE; MISOPROSTOL; PLACEBO; PROSTAGLANDIN E1;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; HEAD AND NECK CANCER; HOSPITAL ADMISSION; HUMAN; MOUTH CARCINOMA; MOUTH HYGIENE; MUCOSA INFLAMMATION; OROPHARYNX CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VISUAL ANALOG SCALE; WEIGHT REDUCTION;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DOUBLE-BLIND METHOD; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MISOPROSTOL; QUALITY OF LIFE; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; SEVERITY OF ILLNESS INDEX; STOMATITIS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 33748667058     PISSN: 00048461     EISSN: 14401673     Source Type: Journal    
DOI: 10.1111/j.1440-1673.2006.01628.x     Document Type: Article

References (26)

1. Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: part 1, pathogenesis and prophylaxis of mucositis. Head Neck 2003; 25: 1057-70.
2. Poland JM. The role of Candida infections as an adverse effect upon head and neck cancer patients undergoing therapeutic radiation and the effect of antimycotic treatment. Mycoses 1989; 32 (Suppl. 2): 39-41.
3. Epstein JB, Silverman S, Paggiarino DA et al. Benzydamine HCL for prophylaxis of radiation-induced oral mucositis. Results from a multicentre, randomized, double-blind, placebo-controlled clinical trial. Cancer 2001; 92: 875-85.
4. Ertekin MV, Koc M, Karslioglu I, Sezen O. Zinc sulphate in the prevention of radiation-induced oropharyngeal mucositis: a prospective, placebo-controlled, randomized study. Int J Radiat Oncol Biol Phys 2003; 58: 167-74.
5. Ferreira PR, Fleck JF, Diehl A et al. Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head Neck 2004; 26: 313-21.
6. Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002; 52: 739-47.
7. Huang EY, Leung SW, Wang CJ et al. Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized study. Int J Radiat Oncol Biol Phys 2003; 46: 535-9.
8. Carter DL, Hebert ME, Smink K, Leopold KA, Clough RL, Brizel DM. Double blind randomized trial of sucralfate vs placebo during radical radiotherapy for head and neck cancers. Head Neck 1999; 21: 760-66.
9. Wijers OB, Levendag PC, Harms ERE et al. Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: a placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys 2001; 50: 343-52.
10. El-Sayed S, Nabid A, Shelley J et al. Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system. J Clin Oncol 2002; 20: 3956-63.
11. Trotti A, Garden A, Warde P et al. A multinational, randomized phase III trial of iseganan HCL oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head and neck malignancy. Int J Radiat Oncol Biol Phys 2004; 58: 674-81.
12. Warde P, O'Sullivan B., Aslanidis et al. A phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002; 54: 9-13.
13. Saarilahti K, Kajanti M, Joensuu T, Kouri M, Joensuu H. Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study. Int J Radiat Oncol Biol Phys 2002; 54: 479-85.
14. Matejka M, Nell A, Kment G et al. Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis. Br J Oral Maxillofac Surg 1990; 28: 89-91.
15. Haynes DR, Whitehouse MW, Vernon-Roberts B. The prostaglandin E1, analogue, misoprostol regulates inflammatory cytokines and immune functions in vitro like the natural prostaglandins E1, E2 and E3. Immunology 1992; 76: 251-7.
16. 1 analog: a placebo-controlled, double-blind clinical trial. Am J Ther 1995; 2: 1-8.
17. 1 analog misoprostol (RTOG 96-07). Int J Radiat Oncol Biol Phys 2002; 54: 1455-9.
18. Clarkson JE, Worthington HV, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment (Cochrane review). In: The Cochrane Library. Chichester, UK: John Wiley & Sons Ltd, 2004.
19. Worthington HV, Clarkson JE, Eden OB. Interventions for treating oral mucositis for patients with cancer receiving treatment (Cochrane review). In: The Cochrane Library. Chichester, UK: John Wiley & Sons Ltd, 2004.
20. Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: part 2 diagnosis and management of mucositis. Head Neck 2003; 25: 77-84.
21. Brizel DM, Wasserman TH, Henke M et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000; 18: 3339-45.
22. Wright JR, McKenzie M, DeAngelis C et al. Radiation induced mucositis: co-ordinating a research agenda. Clin Oncol (R Coll Radiol) 2003; 15: 473-7.
23. Sutherland SE, Browman GP. Prophylaxis of oral mucositis in irradiated head and neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials. Int J Radiat Oncol Biol Phys 2001; 49: 917-30.
24. Peterman A, Cella D, Glandon G, Dobrez D, Yount S. Mucositis in head and neck cancer: economic and quality-of-life outcomes. J Natl Cancer Inst Monogr 2001; 29: 45-51.
25. Trotti A, Bellm LA, Epstein JB et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic review. Radiother Oncol 2003; 66: 252-62.
26. Hanson WR, Zhen W, Geng L, Hunter N, Milas L. The prostaglandin E analog, misoprostol: a normal tissue protector does not protect four murine tumours in vivo from radiation injury. Radiat Res 1995; 142: 281-7.